Table 2.
Depression-related characteristics among respondents with TRD or nTRD
| Parameters | TRD (n = 622) |
nTRD (n = 2686) |
P-value | ||
|---|---|---|---|---|---|
| % | N | % | N | ||
| Family history of depression | 47.7% | 297 | 38.2% | 1026 | <0.001 |
| Participation in talk therapy | 33.3% | 207 | 22.9% | 616 | <0.001 |
| Anxiety | 78.0% | 485 | 61.6% | 1654 | <0.001 |
| Suicide ideation | 17.0% | 106 | 8.2% | 220 | <0.001 |
| Prescription medication use for depression | |||||
| SSRI/SNRI/SARI/NaSSA | 92.6% | 576 | 90.0% | 2417 | <0.001 |
| TeCA/TCA | 21.9% | 136 | 9.7% | 261 | <0.001 |
| Benzodiazepine | 11.3% | 70 | 1.2% | 32 | <0.001 |
| Anti-Psychotics | 8.0% | 50 | 1.0% | 26 | <0.001 |
| NDRI/NRI | 2.9% | 18 | 0.9% | 25 | <0.001 |
| MOAI/RIMA | 1.0% | 6 | .0% | 1 | <0.001 |
MAOI Monoamine oxidase inhibitors, MDD major depressive disorder, nTRD non-treatment resistant depression, NA not applicable, NaSSA Noradrenergic and specific serotonergic antidepressant, NDRI Norepinephrine–dopamine reuptake inhibitors, NRI norepinephrine reuptake inhibitors, RIMA Reversible inhibitors of monoamine oxidase A, SD standard deviation, SSRI Selective serotonin reuptake inhibitors, SNRI Serotonin–norepinephrine reuptake inhibitors, TCA tricyclic antidepressants, TeCA tetracyclic antidepressants, TRD treatment resistant depression